Does Medicaid Cover Wegovy or Zepbound for Weight Loss? A State-by-State Guide for 2026

It depends on your state, and the list keeps getting shorter. In October 2025, KFF counted 16 state Medicaid programs that paid for GLP-1 drugs such as Wegovy (semaglutide), Zepbound (tirzepatide), and Saxenda (liraglutide) when they were prescribed to treat obesity. By January 2026 that number had fallen to 13. Since then, Utah, Massachusetts, and Rhode Island have also stopped paying for the drugs when weight loss is the only reason for the prescription.

As of October 5, 2026, we could confirm that nine state programs still cover GLP-1 drugs for weight loss: Kansas, Michigan, Minnesota, Mississippi, Missouri, North Carolina, Tennessee, Virginia, and Wisconsin. Michigan and Virginia limit that coverage to people with very high body mass index (BMI). Delaware was on KFF's January list, but we could not confirm which drugs it covers now.

The rules below come from state Medicaid documents and news reports, and each one carries a date. Coverage can change with any state budget, so confirm your own plan before you count on it.

Federal law requires state Medicaid programs to cover nearly all FDA-approved drugs from manufacturers that pay Medicaid rebates, but it lists a few exceptions. One of them reads: "Agents when used for anorexia, weight loss, or weight gain." That clause lets each state decide whether to pay for GLP-1 drugs when they are prescribed for weight loss alone.

The exception covers the use, not the drug. KFF notes that states must cover these medicines for other medically accepted uses: type 2 diabetes, lowering the risk of heart attack and stroke (an approved use of Wegovy since March 2024), and moderate to severe obstructive sleep apnea in adults with obesity (an approved use of Zepbound since December 2024). Children can also get coverage when a drug is medically necessary under Medicaid's Early and Periodic Screening, Diagnostic and Treatment (EPSDT) benefit.

In practice, that means someone who loses weight-loss coverage may still qualify under a different diagnosis. Utah's current prior authorization form, for example, still covers Wegovy to prevent heart events, Zepbound for sleep apnea, and Wegovy for MASH, a serious form of fatty liver disease. Prior authorization means your prescriber has to send the plan medical records and get approval before the pharmacy can fill the prescription.

Every state on this list requires prior authorization, and most set a minimum BMI.

North Carolina shows why these programs are under pressure. In June 2026 alone, its Medicaid program paid $47.9 million in GLP-1 weight-loss claims for 34,524 people, before rebates and federal matching funds.

Rhode Island Current counted Rhode Island as at least the seventh state in 2026 to end or not renew Medicaid coverage of GLP-1s for obesity.

North Carolina is the one state that ended coverage and then brought it back. Its Medicaid program stopped paying for weight-loss GLP-1s on October 1, 2025, during a state budget standoff, and Governor Josh Stein restored the benefit on December 12, 2025.

In every other state and the District of Columbia, KFF found in January 2026 that Medicaid did not cover any GLP-1 drug for obesity, and we did not find a state that has added coverage since. KFF noted that seven states (Connecticut, Louisiana, New Hampshire, New Mexico, North Dakota, Pennsylvania, and Texas) cover one or more older weight-loss drugs but no GLP-1s.

Cost drives nearly every one of these decisions. KFF found that gross Medicaid spending on all GLP-1 drugs, for diabetes as well as obesity, rose from about $1 billion in 2019 to almost $9 billion in 2024, before rebates. The average gross cost per prescription reached $1,000, and GLP-1s made up more than 8% of Medicaid's drug spending in 2024, up from 1% in 2019.

KFF also pointed to state budget problems and to the federal Medicaid spending cuts in the 2025 reconciliation law. Michigan expected its narrower coverage to cut $240 million in drug spending, Bridge Michigan reported. In Massachusetts, state officials said that while the drugs work, continuing to pay for them was "unsustainable," WBUR reported.

The cuts land on people who often cannot afford the drugs on their own. Rhode Island Medicaid paid for 24,971 GLP-1 prescriptions for obesity in its 2025 fiscal year, and MassHealth's change affected at least 22,000 members.

The federal government has started two programs, but neither replaces state coverage.

The BALANCE model, announced by the Centers for Medicare & Medicaid Services (CMS) in December 2025, lets state Medicaid programs buy GLP-1 drugs at prices CMS negotiates with the manufacturers, with standard coverage rules and lifestyle support. Participation is voluntary, and states could begin joining in May 2026. As of late August 2026, CMS had not named a single participating state, according to Medical Daily, and patients in the model would still need prior authorization.

The Medicare GLP-1 Bridge matters for people who have both Medicare and Medicaid. Since July 1, 2026, it has offered Foundayo, Wegovy (shot or pill), and Zepbound for a $50 monthly copay to eligible Medicare Part D enrollees, through December 31, 2027. CMS says dual-eligible people in eligible Part D plans can use it if they meet the clinical criteria: a BMI of 35 or more, a BMI of 30 or more with heart failure, uncontrolled high blood pressure, or chronic kidney disease (stage 3a or worse), or a BMI of 27 or more with prediabetes, a past heart attack or stroke, or symptomatic peripheral artery disease. The $50 copay is not reduced by Extra Help, Medicare's low-income subsidy. Our patient guide to the Bridge explains how to apply.

For people who have Medicaid only, the remaining option in states without coverage is paying out of pocket. Self-pay prices fell in 2026; see our guide to TrumpRx and the 2026 GLP-1 price cuts.

Many Medicaid members are enrolled in managed care, meaning a private health plan runs their benefits under a contract with the state. These plans may use their own forms and steps on top of the state's rules. To find out where you stand:

• Look up your state's preferred drug list (PDL). A PDL is the state's list of covered drugs, and it shows which GLP-1 is preferred and whether prior authorization is required.
• Call the member services number on your plan card and ask whether Wegovy, Zepbound, Saxenda, or Foundayo is covered for weight management, and on what terms.
• If you have type 2 diabetes, heart disease, sleep apnea, or MASH, ask your prescriber whether to request approval for that diagnosis instead. States must cover the drugs for medically accepted uses other than weight loss, but the plan will still want records showing you have the condition.
• If a request is denied, read the denial notice. It should explain how to appeal and how long you have to do it.

For people with private insurance or employer coverage, our guide to GLP-1 insurance coverage and prior authorization walks through the same steps.